Morpholino

MO1-mlxip

ID

ZDB-MRPHLNO-201111-1

Name

MO1-mlxip

Previous Names

None

Target

Sequence

5' - GGTATTGTCGAGTAGCCATGTTAAA - 3'

Disclaimer

Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.

Note

Translation-blocking MO.

Genome Resources

None

Target Location

Genomic Features

No data available

Expression

Gene expression in Wild Types + MO1-mlxip

No data available

Phenotype

Phenotype resulting from MO1-mlxip

Phenotype	Fish	Figures
cell microtubule decreased length, abnormal	WT + MO1-mlxip	Figure 6. from Weger et al., 2020
cell microtubule morphology, abnormal	WT + MO1-mlxip	Figure 6. from Weger et al., 2020
cell motility disrupted, abnormal	kca6Tg + MO1-mlxip	Figure 3 from Weger et al., 2020
epiboly delayed, abnormal	kca6Tg + MO1-mlxip	Figure 2 , Figure 3 from Weger et al., 2020
epiboly disrupted, abnormal	WT + MO1-mlxip	Figure 4 from Weger et al., 2020
yolk syncytial layer disorganized, abnormal	kca6Tg + MO1-mlxip	Figure 4 from Weger et al., 2020

Phenotype of all Fish created by or utilizing MO1-mlxip

Phenotype	Fish	Conditions	Figures
cell microtubule morphology, ameliorated	WT + MO1-mlxip	chemical treatment by injection: pregnenolone	Figure 6. from Weger et al., 2020
epiboly delayed, abnormal	WT + MO1-mlxip	standard conditions	Figure 2 from Weger et al., 2020
epiboly disrupted, abnormal	WT + MO1-mlxip	standard conditions	Figure 4 from Weger et al., 2020
cell microtubule morphology, abnormal	WT + MO1-mlxip	standard conditions	Figure 6. from Weger et al., 2020
cell microtubule decreased length, abnormal	WT + MO1-mlxip	standard conditions	Figure 6. from Weger et al., 2020
yolk syncytial layer disorganized, abnormal	kca6Tg + MO1-mlxip	standard conditions	Figure 4 from Weger et al., 2020
epiboly delayed, abnormal	kca6Tg + MO1-mlxip	standard conditions	Figure 3 from Weger et al., 2020
cell motility disrupted, abnormal	kca6Tg + MO1-mlxip	standard conditions	Figure 3 from Weger et al., 2020
whole organism nsdhl expression increased amount, abnormal	WT + MO1-mlx + MO1-mlxip	chemical treatment by injection: 2-deoxy-D-glucose	Figure 5 from Weger et al., 2020
whole organism nsdhl expression increased amount, abnormal	WT + MO1-mlx + MO1-mlxip	control	Figure 5 from Weger et al., 2020

Citations